SAB Biotherapeutics (SABS) Debt to Equity (2020 - 2022)
SAB Biotherapeutics (SABS) reported Debt to Equity of $0.02 for Q4 2022, up 295.43% quarter-over-quarter from $0.0 in Q4 2020.
SAB Biotherapeutics (SABS) Debt to Equity (2020 - 2022) Analysis & Trends
SAB Biotherapeutics has reported Debt to Equity for 2 years, with the latest figure at $0.02 in Q4 2022.
- For the quarter ending Q4 2022, Debt to Equity changed N/A year-over-year to $0.02; the trailing twelve-month figure through Dec 2022 stood at $0.02 (changed N/A YoY), and the FY2022 full-year result was $0.02, changed N/A from the prior year.
- Debt to Equity for Q4 2022 stood at $0.02, up from $0.0 in the prior quarter.
- The five-year high for Debt to Equity was $0.02 in Q4 2022, with the low at $0.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.02 |
| Dec 31, 2020 | 0.00 |